Compare KOP & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOP | ETON |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.3M | 689.8M |
| IPO Year | 2005 | 2018 |
| Metric | KOP | ETON |
|---|---|---|
| Price | $40.91 | $30.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $52.50 | $39.33 |
| AVG Volume (30 Days) | 165.5K | ★ 420.7K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 11.38 | N/A |
| EPS | ★ 0.35 | 0.05 |
| Revenue | ★ $1,879,300,000.00 | $79,950,000.00 |
| Revenue This Year | $2.91 | $40.90 |
| Revenue Next Year | $1.86 | $47.23 |
| P/E Ratio | ★ $117.94 | $638.20 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $25.00 | $13.09 |
| 52 Week High | $46.40 | $35.66 |
| Indicator | KOP | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 51.68 |
| Support Level | $37.35 | $16.23 |
| Resistance Level | $42.17 | $32.31 |
| Average True Range (ATR) | 1.53 | 1.92 |
| MACD | -0.13 | -0.31 |
| Stochastic Oscillator | 42.51 | 28.79 |
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.